Pulse Biosciences (NASDAQ:PLSE) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, ValuEngine reports.
Separately, BidaskClub raised Pulse Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, September 26th.
NASDAQ PLSE traded up $0.62 on Monday, reaching $15.70. 57,952 shares of the stock traded hands, compared to its average volume of 56,786. The firm’s fifty day simple moving average is $14.60 and its 200 day simple moving average is $13.38. The company has a quick ratio of 12.92, a current ratio of 12.92 and a debt-to-equity ratio of 0.07. The company has a market cap of $302.60 million, a price-to-earnings ratio of -7.14 and a beta of 1.88. Pulse Biosciences has a 12 month low of $8.60 and a 12 month high of $19.77.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Pulse Biosciences during the 2nd quarter worth $55,000. Bank of Montreal Can boosted its stake in shares of Pulse Biosciences by 15.0% during the 2nd quarter. Bank of Montreal Can now owns 8,053 shares of the company’s stock worth $106,000 after acquiring an additional 1,053 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Pulse Biosciences by 7.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,993 shares of the company’s stock worth $357,000 after acquiring an additional 1,853 shares in the last quarter. Griffin Asset Management Inc. boosted its stake in shares of Pulse Biosciences by 11.6% during the 2nd quarter. Griffin Asset Management Inc. now owns 57,315 shares of the company’s stock worth $757,000 after acquiring an additional 5,955 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Pulse Biosciences by 2.0% during the 2nd quarter. Northern Trust Corp now owns 124,276 shares of the company’s stock worth $1,640,000 after acquiring an additional 2,454 shares in the last quarter. 9.88% of the stock is owned by institutional investors and hedge funds.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
Featured Story: What causes a recession?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.